S. Leaw

发表

Internal mammary lymph node recurrence: rare but characteristic metastasis site in breast cancer

Jin-song Lu, Z. Shao, Jiayi Chen, 2010, BMC Cancer.

The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects

Jian-hua Chang, Jian Zhang, Xichun Hu, 2011, Medical oncology.

Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy

W. Su, C. Yen, C. Tsao, 2004, Annals of Hematology.

An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study

Jin-song Lu, Z. Shao, Jialei Wang, 2012, Cancer Chemotherapy and Pharmacology.

Cholangiocarcinoma presenting as lung mass with hemoptysis

T.-Y. Lee, S. Leaw, Y.-F. Cheng, 1999, Abdominal Imaging.

Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis

Jialei Wang, Jiafeng Gao, Jian Zhang, 2010, Breast Cancer Research and Treatment.

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

N. Yang, K. Ying, Zhijie Wang, 2021, JAMA oncology.

Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer

Jie Luo, S. Leaw, Ying Xu, 2011, Medical oncology.

XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population.

W. Tan, D. Lin, Bing-he Xu, 2008, Lung cancer.

RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.

Ji-Rong Wen, Xiaozhong Chen, Guihua Wang, 2022, Journal of Clinical Oncology.

Clinical features and treatment outcomes of 14 cases of primary ovarian non-Hodgkin’s lymphoma: a single-center experience

Jian-hua Chang, X. Hong, S. Leaw, 2011, Medical oncology.

A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.

Ying Cheng, Y. Shu, Zhijie Wang, 2020, Lung cancer.

132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis

K. Yang, S. Lu, Y. Song, 2022, Immuno-Oncology and Technology.

The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial.

J. Wang, S. Leaw, Y. Bao, 2021, Cancer treatment and research communications.

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).

Hong Wang, Jianji Pan, Xiaozhong Chen, 2023, Cancer cell.

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.

Dingzhi Huang, S. Leaw, Xingya Li, 2024, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA01.06 First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study

W. Zheng, S. Leaw, D. Huang, 2023, Journal of Thoracic Oncology.

Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma

Zhirong Shen, J. Duan, Jun Zhao, 2023, Cell reports. Medicine.